In vivo imaging of cell proliferation enables the detection of the extent of experimental rheumatoid arthritis by 3′-deoxy-3′- 18F-fluorothymidine and small-animal PET

Journal of Nuclear Medicine

Volumn 54, Issue 1, 2013, Pages 51-158

  Fuchs, Kerstin ^a   Kohlhofer, Ursula ^a   Quintanilla Martinez, Leticia ^a   Lamparter, Denis ^a   Kötter, Ina ^a   Reischl, Gerald ^a   Röcken, Martin ^a   Pichler, Bernd J ^a   Kneilling, Manfred ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

18F FLT; Animal model; Autoimmune disease; In vivo imaging; Rheumatoid arthritis

Indexed keywords

3' FLUOROTHYMIDINE F 18; KI 67 ANTIGEN; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT; GLUCOSE 6 PHOSPHATE ISOMERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; DRUG UPTAKE; EXPERIMENTAL STUDY; FEASIBILITY STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIMB SWELLING; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RHEUMATOID ARTHRITIS; ANIMAL; BAGG ALBINO MOUSE; CHEMICALLY INDUCED DISORDER; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ARTHRITIS, RHEUMATOID; BIOLOGICAL TRANSPORT; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION REGULATION; GLUCOSE-6-PHOSPHATE ISOMERASE; KI-67 ANTIGEN; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED BALB C; POSITRON-EMISSION TOMOGRAPHY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY;

MLCS; MLOWN;

EID: 84872019649     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.106740     Document Type: Article

References (42)

1. Harris ED Jr. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med. 1990;322:1277-1289.
2. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358:903-911.
3. Firestein GS. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J Clin Rheumatol. 2005;11(suppl):S39-S44.
4. Kneilling M, Hultner L, Pichler BJ, et al. Targeted mast cell silencing protects against joint destruction and angiogenesis in experimental arthritis in mice. Arthritis Rheum. 2007;56:1806-1816.
5. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:614-624.
6. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594-1602.
7. van den Broek M, Huizinga TW, Dijkmans BA, Allaart CF. Drug-free remission: is it already possible? Curr Opin Rheumatol. 2011;23:266-272.
8. Nowosinska E, Avril S, Murray I, Szyszko T, Avril N. FDG-PET/CT as a molecular biomarker in ovarian cancer. Cancer Biomark. 2010;8:167-175.
9. Avril N. Metabolic FDG-PET imaging in breast cancer: implications for treatment stratification. Nat Clin Pract Oncol. 2007;4:336-337.
10. Gompels LL, Paleolog EM. A window on disease pathogenesis and potential therapeutic strategies: molecular imaging for arthritis. Arthritis Res Ther. 2011;13:201.
11. Hammer HB, Haavardsholm EA. Advances in imaging. Curr Opin Rheumatol. 2012;24:299-305.
12. Kubota K, Ito K, Morooka M, et al. FDG PET for rheumatoid arthritis: basic considerations and whole-body PET/CT. Ann N Y Acad Sci. 2011;1228:29-38.
13. Cheung PP, Dougados M, Gossec L. Reliability of ultrasonography to detect synovitis in rheumatoid arthritis: a systematic literature review of 35 studies (1,415 patients). Arthritis Care Res (Hoboken). 2010;62:323-334.
14. Reynolds A. Imaging rheumatic diseases. Radiol Technol. 2012;83:467-489.
15. 18F-FDG PET studies in mice. J Nucl Med. 2006;47:999-1006.
16. Hawkins RA, Choi Y, Huang SC, Messa C, Hoh CK, Phelps ME. Quantitating tumor glucose metabolism with FDG and PET. J Nucl Med. 1992;33:339-344.
17. Palmer WE, Rosenthal DI, Schoenberg OI, et al. Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1995;196:647-655.
18. 18F-FDG PET. J Nucl Med. 2004;45:956-964.
19. 18F-FDG positron emission tomography and computed tomography. Arthritis Res Ther. 2010;12:R203.
20. Yoshida S, Higuchi F, Ishibashi Y, et al. Downregulation of RCAS1 and upregulation of cytotoxic T cells affects synovial proliferation and apoptosis in rheumatoid arthritis. J Rheumatol. 2008;35:1716-1722.
21. 18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging. 2004;31:1659-1672.
22. 18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007;34:1339-1347.
23. 18F-fluorothymidine PET. J Nucl Med. 2005;46:114-120.
24. Pio BS, Park CK, Pietras R, et al. Usefulness of 3′-[F-18]fluoro- 3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2006;8:36-42.
25. Paproski RJ, Ng AM, Yao SY, Graham K, Young JD, Cass CE. The role of human nucleoside transporters in uptake of 3′-deoxy-3′- fluorothymidine. Mol Pharmacol. 2008;74:1372-1380.
26. 18F-FLT in cancer imaging: does it really reflect proliferation? Eur J Nucl Med Mol Imaging. 2008;35:523-526.
27. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336.
28. Krohn KA, Mankoff DA, Eary JF. Imaging cellular proliferation as a measure of response to therapy. J Clin Pharmacol. 2001;July(suppl):96S-103S.
29. 18F]-fluorothymidine uptake in human tumor xenograft models. Mol Imaging Biol. 2012;14:355-365.
30. van Waarde A, Jager PL, Ishiwata K, Dierckx RA, Elsinga PH. Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation. J Nucl Med. 2006;47:150-154.
31. 18F-fluorothymidine uptake in mouse models of arthritis and cancer. J Nucl Med. 2012;53:823-830.
32. Constantinescu CC, Mukherjee J. Performance evaluation of an Inveon PET preclinical scanner. Phys Med Biol. 2009;54:2885-2899.
33. Dardzinski BJ, Schmithorst VJ, Holland SK, et al. MR imaging of murine arthritis using ultrasmall superparamagnetic iron oxide particles. Magn Reson Imaging. 2001;19:1209-1216.
34. Kouskoff V, Korganow AS, Duchatelle V, Degott C, Benoist C, Mathis D. Organ-specific disease provoked by systemic autoimmunity. Cell. 1996;87:811-822.
35. Korganow AS, Ji H, Mangialaio S, et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity. 1999;10:451-461.
36. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311-322.
37. 18F-FLT PET studies in lung tumors. J Nucl Med. 2011;52:1181-1188.
38. Canat X, Guillaumont A, Bouaboula M, et al. Peripheral benzodiazepine receptor modulation with phagocyte differentiation. Biochem Pharmacol. 1993;46:551-554.
39. 11C-(R)-PK11195 and positron emission tomography. Arthritis Rheum. 2008;58:3350-3355.
40. 18F-fluorothymidine PET/CT as an early predictor of tumor response to treatment with cetuximab in human lung cancer xenografts. Oncol Rep. 2011;26:725-730.
41. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model. J Nucl Med. 2010;51:1559-1564.
42. 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study. J Nucl Med. 2010;51:528-534.